- QMRO Home
- Barts Cancer Institute
- Centre for Haemato-Oncology
- Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
Browse
Administrators only